SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced the closing of its previously announced underwritten public offering of 8,048,782 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 1,097,561 additional shares, at a ...

The company aims to raise gross proceeds of roughly $300 million in a new capital-raising effort.Apogee Therapeutics (APGE 12.64%) stock was the cure for many an ailing stock portfolio on the second-to-last trading day of the week. The company's shares got a boost from some encouraging news on the financing front, and they closed the day nearly 13% higher in value. It's an understatement to say this compared favorably to the S&P 500's (^GSPC -0.28%) 0.3% decline.New stock on the wayApogee, a clinical-stage ...

U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.1% on Thursday.Shares of Helen of Troy Ltd (NASDAQ:HELE) fell sharply in today's pre-market trading following second-quarter results.Helen Of Troy reported quarterly earnings of 59 cents per share which beat the analyst consensus estimate of 53 cents per share. The company reported quarterly sales of $431.781 million which beat the analyst consensus estimate of $418.806 millionHelen Of Troy said it sees FY2026 adju ...

U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.1% on Thursday.Shares of Helen of Troy Ltd (NASDAQ:HELE) fell sharply in today's pre-market trading following second-quarter results.Helen Of Troy reported quarterly earnings of 59 cents per share which beat the analyst consensus estimate of 53 cents per share. The company reported quarterly sales of $431.781 million which beat the analyst consensus estimate of $418.806 millionHelen Of Troy said it sees FY2026 adju ...

Core Viewpoint - Apogee Therapeutics, Inc. has announced a public offering of 6,951,221 shares of common stock priced at $41.00 per share, aiming to raise approximately $300 million before expenses [1]. Group 1: Offering Details - The offering includes pre-funded warrants for certain investors to purchase up to 365,853 shares at a price of $40.99999 per warrant, with an exercise price of $0.00001 per share [1]. - The offering is expected to close on October 10, 2025, subject to customary closing conditions [1]. - Underwriters have an option to purchase an additional 1,097,561 shares at the public offering price within 30 days [1]. Group 2: Underwriters - Jefferies, BofA Securities, Guggenheim Securities, and TD Cowen are acting as joint book-running managers for the offering, while BTIG serves as a passive bookrunner [2]. Group 3: Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology markets, including treatments for Atopic Dermatitis, asthma, Eosinophilic Esophagitis, and Chronic Obstructive Pulmonary Disease [5]. - The company's lead program, APG777, targets Atopic Dermatitis, which is noted as a large and under-penetrated market [5]. - Apogee aims to achieve best-in-class profiles through its antibody programs by addressing limitations of existing therapies and optimizing properties such as half-life [5].

SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In additi ...

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best strong buy stocks to invest in according to Wall Street. On September 25, RBC Capital initiated coverage of Apogee Therapeutics Inc. (NASDAQ:APGE) with an Outperform rating and a $60 price target. Is Exact Sciences Corporation (NASDAQ:EXAS) the Gene Therapy Stock with the Greatest Potential? The firm expressed optimistic sentiments regarding the company’s potential to deliver clinically differentiated biologics, telling investors in a research not ...

Summary of Apogee Therapeutics Conference Call Company Overview - **Company**: Apogee Therapeutics (NasdaqGM:APGE) - **Focus**: Development of mono and combination therapies for atopic dermatitis (AD) and other indications, with a strong emphasis on IL-13 antibody therapies [3][4] Key Points Industry Dynamics - The biologic market for atopic dermatitis is experiencing significant growth, with a **25% increase** year-over-year and a **48% rise** in new-to-brand prescriptions [7][8] - Current biologic penetration in the AD market is only about **10%**, indicating substantial room for growth [7] - New entrants like Eplis and Nimolizumab are performing well, with Eplis growing **40%** from Q1 to Q2 and Nimolizumab over **100%** in the same period [8] Product Development and Pipeline - Apogee is focused on launching a best-in-class therapy for atopic dermatitis later in the decade, with ongoing Phase 2 studies and combination studies planned for next year [3][4] - The company aims to innovate continuously in the atopic dermatitis space, with a focus on creating therapies that can be co-formulated and administered together [4] - The Phase 2a study showed a **66.9%** response rate in achieving EZ 75, a key endpoint for physicians [14] - Early itch relief was statistically significant as early as one week after treatment, with a focus on reducing the number of injections required compared to competitors [16][17] Safety and Efficacy - The safety profile of Apogee's therapies is comparable to existing treatments like Dupixent and Lebrikizumab, with a focus on managing adverse events such as conjunctivitis [22][24] - The company reported **zero injection site reactions** in their study, a significant advantage over competitors [26] Future Studies and Market Strategy - Ongoing studies include a Phase 2b trial with a readout expected in mid-2026, focusing on dose-response and maintenance of efficacy [30][34] - The company is exploring both quarterly and biannual dosing options, which could enhance market share by **10%** among physicians [41] - Apogee is also considering expansion into asthma indications due to overlap with atopic dermatitis patients [62] Financial Position - Apogee has a strong balance sheet with **$620 million** in cash, providing a runway into **2028** to support ongoing and future studies [58][62] Additional Insights - The company emphasizes the importance of data disclosure and market research to inform their strategies and product development [20][21] - Apogee's approach to combination therapies is based on optimizing the therapeutic profile without the risks associated with bispecific antibodies [44][46] - The company is committed to being a "serial innovator" in atopic dermatitis, prioritizing capital allocation towards this goal [58][62]

Company Overview - Apogee Therapeutics Inc. (NASDAQ:APGE) is a clinical-stage biotechnology company focused on developing novel biologics for treating atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications [4] Financial Performance - As of the end of Q2 2025, Apogee Therapeutics reported a strong cash position of $621.2 million in cash, cash equivalents, and marketable securities, which is expected to support operations into Q1 2028 [2] Recent Developments - BofA analyst Tim Anderson raised the price target for Apogee Therapeutics to $87 from $78, maintaining a Buy rating, following positive changes in estimates after the Q2 2025 results [1] - The company announced positive topline data from Part A of its Phase 2 APEX trial for APG777, a potential best-in-class treatment for moderate-to-severe atopic dermatitis, achieving a 71% reduction in the Eczema Area and Severity Index from baseline, compared to 33.8% for placebo [3]

Core Insights - Apogee Therapeutics, Inc. announced that data from the Phase 2 APEX trial of APG777 for moderate-to-severe atopic dermatitis will be presented at the EADV Congress 2025 in Paris, highlighting its potential as a best-in-class treatment [1][2] Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology markets, including atopic dermatitis, asthma, and chronic obstructive pulmonary disease [4][5] - The company aims to create best-in-class profiles through advanced antibody engineering and targeting established mechanisms of action [4][5] Clinical Trial Highlights - The APEX trial demonstrated that APG777 met both primary and secondary endpoints, reinforcing its potential as a leading treatment option for moderate-to-severe atopic dermatitis [2] - APG777 is notable for being the only biologic tested with maintenance dosing every 3 and 6 months [2] - The combination of APG777 with APG990, which targets OX40L, is expected to broaden the treatment scope for various inflammatory conditions [2] Presentation Details at EADV Congress 2025 - A late-breaker oral presentation titled "APG777, a Novel, Half-Life Extended Anti-IL-13 Antibody, Demonstrates Safety and Efficacy in Moderate-to-Severe Atopic Dermatitis: 16-Week Results from the Phase 2 APEX Study" will be presented by Dr. Emma Guttman-Yassky on September 19, 2025 [3] - Multiple poster presentations will also be featured, including studies on APG777 and APG990, showcasing their safety profiles and efficacy [3]